Allogene Therapeutics Net Income
| ALLO Stock | USD 1.80 0.18 11.11% |
As of the 17th of February 2026, Allogene Therapeutics shows the Risk Adjusted Performance of 0.125, downside deviation of 4.93, and Mean Deviation of 4.08. Allogene Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Allogene Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 3.9 K | Earnings Share (0.98) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -231.8 M | -243.4 M | |
| Net Loss | -299.4 M | -314.3 M | |
| Net Loss | -231.8 M | -243.4 M | |
| Net Loss | (1.52) | (1.60) | |
| Net Income Per E B T | 0.90 | 0.62 |
Allogene | Net Income | Build AI portfolio with Allogene Stock |
Evaluating Allogene Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Allogene Therapeutics's fundamental strength.
Latest Allogene Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Allogene Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Allogene Therapeutics financial statement analysis. It represents the amount of money remaining after all of Allogene Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Allogene Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Allogene Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (257.59 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Allogene Net Income Regression Statistics
| Arithmetic Mean | (133,196,856) | |
| Coefficient Of Variation | (100.53) | |
| Mean Deviation | 125,359,864 | |
| Median | (184,594,000) | |
| Standard Deviation | 133,905,845 | |
| Sample Variance | 17930.8T | |
| Range | 329.8M | |
| R-Value | (0.87) | |
| Mean Square Error | 4511.7T | |
| R-Squared | 0.76 | |
| Slope | (23,179,650) | |
| Total Sum of Squares | 286892.4T |
Allogene Net Income History
Other Fundumenentals of Allogene Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Allogene Therapeutics Net Income component correlations
Allogene Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Allogene Therapeutics is extremely important. It helps to project a fair market value of Allogene Stock properly, considering its historical fundamentals such as Net Income. Since Allogene Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Allogene Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Allogene Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Allogene diversify its offerings? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Allogene Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Allogene Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Allogene Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Allogene Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Allogene Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Allogene Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Allogene Therapeutics.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Allogene Therapeutics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Allogene Therapeutics or generate 0.0% return on investment in Allogene Therapeutics over 90 days. Allogene Therapeutics is related to or competes with Editas Medicine, Cabaletta Bio, Caribou Biosciences, Atea Pharmaceuticals, Humacyte, Vanda Pharmaceuticals, and Voyager Therapeutics. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineere... More
Allogene Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Allogene Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Allogene Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.93 | |||
| Information Ratio | 0.1315 | |||
| Maximum Drawdown | 26.97 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 11.11 |
Allogene Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Allogene Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Allogene Therapeutics' standard deviation. In reality, there are many statistical measures that can use Allogene Therapeutics historical prices to predict the future Allogene Therapeutics' volatility.| Risk Adjusted Performance | 0.125 | |||
| Jensen Alpha | 0.675 | |||
| Total Risk Alpha | 0.3707 | |||
| Sortino Ratio | 0.1447 | |||
| Treynor Ratio | 0.469 |
Allogene Therapeutics February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.125 | |||
| Market Risk Adjusted Performance | 0.479 | |||
| Mean Deviation | 4.08 | |||
| Semi Deviation | 4.04 | |||
| Downside Deviation | 4.93 | |||
| Coefficient Of Variation | 692.52 | |||
| Standard Deviation | 5.43 | |||
| Variance | 29.47 | |||
| Information Ratio | 0.1315 | |||
| Jensen Alpha | 0.675 | |||
| Total Risk Alpha | 0.3707 | |||
| Sortino Ratio | 0.1447 | |||
| Treynor Ratio | 0.469 | |||
| Maximum Drawdown | 26.97 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 11.11 | |||
| Downside Variance | 24.35 | |||
| Semi Variance | 16.32 | |||
| Expected Short fall | (5.42) | |||
| Skewness | 0.5068 | |||
| Kurtosis | 0.8486 |
Allogene Therapeutics Backtested Returns
Allogene Therapeutics appears to be very risky, given 3 months investment horizon. Allogene Therapeutics secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of risk over the last 3 months. By analyzing Allogene Therapeutics' technical indicators, you can evaluate if the expected return of 0.75% is justified by implied risk. Please makes use of Allogene Therapeutics' Risk Adjusted Performance of 0.125, mean deviation of 4.08, and Downside Deviation of 4.93 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Allogene Therapeutics holds a performance score of 10. The firm shows a Beta (market volatility) of 1.65, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Allogene Therapeutics will likely underperform. Please check Allogene Therapeutics' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Allogene Therapeutics' price patterns will revert.
Auto-correlation | 0.27 |
Poor predictability
Allogene Therapeutics has poor predictability. Overlapping area represents the amount of predictability between Allogene Therapeutics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Allogene Therapeutics price movement. The serial correlation of 0.27 indicates that nearly 27.0% of current Allogene Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.27 | |
| Spearman Rank Test | 0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Allogene Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Allogene Therapeutics reported net income of (257.59 Million). This is 175.48% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 145.11% higher than that of the company.
Allogene Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Allogene Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Allogene Therapeutics could also be used in its relative valuation, which is a method of valuing Allogene Therapeutics by comparing valuation metrics of similar companies.Allogene Therapeutics is currently under evaluation in net income category among its peers.
Allogene Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Allogene Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Allogene Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Allogene Therapeutics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 3.8 M | Wildcat Capital Management, Llc | 2025-06-30 | 2.9 M | Foresite Capital Management Vi Llc | 2025-06-30 | 2.9 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 2.7 M | State Street Corp | 2025-06-30 | 2.7 M | Patient Square Capital | 2025-06-30 | 2.6 M | Ubs Group Ag | 2025-06-30 | 2 M | Vida Ventures Advisors, Llc | 2025-03-31 | 1.8 M | Two Sigma Advisers, Llc | 2025-06-30 | 1.8 M | Pfizer Inc | 2025-06-30 | 22 M | Tpg Gp A, Llc | 2025-06-30 | 18.7 M |
Allogene Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 229.45 M | ||||
| Shares Outstanding | 224.73 M | ||||
| Shares Owned By Insiders | 16.60 % | ||||
| Shares Owned By Institutions | 67.30 % | ||||
| Number Of Shares Shorted | 18.82 M | ||||
| Price To Earning | (3.30) X | ||||
| Price To Book | 1.28 X | ||||
| Price To Sales | 11,631 X | ||||
| Revenue | 22 K | ||||
| Gross Profit | (166.49 M) | ||||
| EBITDA | (243.33 M) | ||||
| Net Income | (257.59 M) | ||||
| Cash And Equivalents | 490.49 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 90.76 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 11.42 X | ||||
| Book Value Per Share | 1.41 X | ||||
| Cash Flow From Operations | (200.3 M) | ||||
| Short Ratio | 3.11 X | ||||
| Earnings Per Share | (0.98) X | ||||
| Price To Earnings To Growth | (4.18) X | ||||
| Target Price | 7.38 | ||||
| Number Of Employees | 226 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 404.51 M | ||||
| Total Asset | 548.71 M | ||||
| Retained Earnings | (1.82 B) | ||||
| Working Capital | 267.86 M | ||||
| Current Asset | 418.72 M | ||||
| Current Liabilities | 26.36 M | ||||
| Net Asset | 548.71 M |
About Allogene Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Allogene Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allogene Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allogene Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
| 0.82 | OSE | OSE Pharma SA | PairCorr |
| 0.72 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.62 | DRMA | Dermata Therapeutics | PairCorr |
| 0.48 | VCEL | Vericel Corp Ord | PairCorr |
| 0.48 | CDIOW | Cardio Diagnostics | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could Allogene diversify its offerings? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Allogene Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Allogene Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Allogene Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Allogene Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.